Skip to main content
Premium Trial:

Request an Annual Quote

Plexpress, Phalanx Partner to Offer Gene Expression Service

NEW YORK (GenomeWeb News) – Plexpress today announced it has partnered with Phalanx Biotech Group to offer a new service allowing researchers to discover, select, and validate biomarkers in a streamlined integrated workflow.

Called OneTRAC, the service profiles genome-wide expression patterns for mRNAs and microRNAs using Phalanx's OneArray microarrays to determine genes of interest and infer gene expression relationships. Once biomarker signatures are identified, target genes can be validated and further researched with Plexpress's Fast TRAC gene expression analysis platform. With OneTRAC, scientists can scale the number of profiled samples across multiple conditions and move from discovery phase to understanding the biological function of the biomarkers, Plexpress said.

"With continued interest among drug sponsors to supplement US regulatory submission with toxicogenomic data, we believe the flexibility and scalability of OneTRAC will be well received by customers investigating expression profiling at both the genome-wide and focused-gene levels," Vivien Mak, president of Phalanx, said in a statement.

Jari Rautio, CEO of Plexpress, added, "By combining the coverage breadth of OneArray microarrays and the high-throughput, multiplex capabilities of TRAC, OneTRAC offers researchers in industry and academia an integrated approach towards identifying, selecting, and validating a robust set of gene expression signatures."

Based in Helsinki, Finland, Plexpress offers high content gene expression analysis for cell biology research. In April, it raised $2.3 million.

Financial and other terms of the alliance were not disclosed.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more